CN111447941B - 用于细胞内递送装订肽的多肽缀合物 - Google Patents

用于细胞内递送装订肽的多肽缀合物 Download PDF

Info

Publication number
CN111447941B
CN111447941B CN201880070271.0A CN201880070271A CN111447941B CN 111447941 B CN111447941 B CN 111447941B CN 201880070271 A CN201880070271 A CN 201880070271A CN 111447941 B CN111447941 B CN 111447941B
Authority
CN
China
Prior art keywords
peptide
cpp
binding
amino acid
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880070271.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111447941A (zh
Inventor
裴德华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Priority to CN202311469512.8A priority Critical patent/CN117567639A/zh
Publication of CN111447941A publication Critical patent/CN111447941A/zh
Application granted granted Critical
Publication of CN111447941B publication Critical patent/CN111447941B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880070271.0A 2017-10-27 2018-10-28 用于细胞内递送装订肽的多肽缀合物 Active CN111447941B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311469512.8A CN117567639A (zh) 2017-10-27 2018-10-28 用于细胞内递送装订肽的多肽缀合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762578213P 2017-10-27 2017-10-27
US62/578,213 2017-10-27
PCT/US2018/057894 WO2019084528A1 (en) 2017-10-27 2018-10-28 POLYPEPTIDE CONJUGATES FOR INTRACELLULAR ADMINISTRATION OF STAPLED PEPTIDES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311469512.8A Division CN117567639A (zh) 2017-10-27 2018-10-28 用于细胞内递送装订肽的多肽缀合物

Publications (2)

Publication Number Publication Date
CN111447941A CN111447941A (zh) 2020-07-24
CN111447941B true CN111447941B (zh) 2023-10-31

Family

ID=66247031

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880070271.0A Active CN111447941B (zh) 2017-10-27 2018-10-28 用于细胞内递送装订肽的多肽缀合物
CN202311469512.8A Pending CN117567639A (zh) 2017-10-27 2018-10-28 用于细胞内递送装订肽的多肽缀合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311469512.8A Pending CN117567639A (zh) 2017-10-27 2018-10-28 用于细胞内递送装订肽的多肽缀合物

Country Status (6)

Country Link
US (2) US11510991B2 (enExample)
EP (1) EP3700548A4 (enExample)
JP (2) JP7780253B2 (enExample)
CN (2) CN111447941B (enExample)
CA (1) CA3080617A1 (enExample)
WO (1) WO2019084528A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12115224B2 (en) 2017-10-27 2024-10-15 Ohio State Innovation Foundation Polypeptide conjugates for intracellular delivery of stapled peptides

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11339192B2 (en) 2017-10-04 2022-05-24 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
EP3746105A4 (en) 2018-01-29 2022-05-18 Ohio State Innovation Foundation CYCLIC PEPTIDYLIN HIBITORS OF THE CAL-PDZ-BINDING DOMAIN
WO2021041895A1 (en) * 2019-08-30 2021-03-04 Ohio State Innovation Foundation Stapled beta-catenin ligands
CN112245593B (zh) * 2020-10-30 2022-05-13 西南交通大学 具有疏水性侧链的稳定化细胞穿膜肽及制备方法与应用
US20240360179A1 (en) * 2021-06-08 2024-10-31 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof
EP4448543A1 (en) 2022-01-06 2024-10-23 Oak Crest Institute of Science Subdermal implant for sustained drug delivery

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015148620A2 (en) * 2014-03-25 2015-10-01 University Of Utah Research Foundation Peptide inhibitors of bcr-abl oligomerization
CN106852146A (zh) * 2014-05-21 2017-06-13 塞克洛波特斯公司 细胞穿透肽及其制备和使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2352555A1 (en) 1998-11-26 2000-06-08 Pentapharm Ag Transport system conjugate
US7033597B2 (en) 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
CA2425610A1 (en) 2000-10-13 2002-04-18 University Of Lausanne Intracellular delivery of biological effectors by novel transporter peptide sequences
SG11201404648PA (en) 2012-02-15 2014-09-26 Aileron Therapeutics Inc Peptidomimetic macrocycles
WO2013150338A1 (en) * 2012-04-04 2013-10-10 Centre National De La Recherche Scientifique Stapled cell penetrating peptides for intracellular delivery of molecules
CN104822698B (zh) 2012-07-11 2018-08-10 珍白斯凯尔有限公司 细胞穿透肽以及包含该肽的缀合物和组合物
US10294273B2 (en) 2014-04-02 2019-05-21 University Of Rochester Macrocyclic peptidomimetics for alpha-helix mimicry
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
WO2017147283A1 (en) * 2016-02-23 2017-08-31 Dana-Farber Cancer Institute, Inc. Method for generating cell-penetrating stapled peptides that lack nonspecific membrane-lytic properties for therapeutic targeting
WO2018089648A2 (en) 2016-11-09 2018-05-17 Ohio State Innovation Foundation Di-sulfide containing cell penetrating peptides and methods of making and using thereof
US20190309020A1 (en) 2016-11-22 2019-10-10 Ohio State Innovation Foundation Cell-penetrating peptide sequences
TW202500573A (zh) 2016-11-22 2025-01-01 俄亥俄州立創新基金會 細胞穿透肽序列
EP3700548A4 (en) 2017-10-27 2021-07-21 Ohio State Innovation Foundation POLYPEPTIDE CONJUGATES FOR THE INTRACELLULAR DELIVERY OF STONED PEPTIDES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015148620A2 (en) * 2014-03-25 2015-10-01 University Of Utah Research Foundation Peptide inhibitors of bcr-abl oligomerization
CN106852146A (zh) * 2014-05-21 2017-06-13 塞克洛波特斯公司 细胞穿透肽及其制备和使用方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Acetone-Linked Peptides: A Convergent Approach for Peptide Macrocyclization and Labeling;Naila Assem等;Angew. Chem.;第第54卷卷(第第54卷期);第8789–8792页 *
Enhancing the Cell Permeability and Metabolic Stability of Peptidyl Drugs by Reversible Bicyclization;Ziqing Qian等;Angew.Chem.;第第56卷卷(第第56卷期);第1525–1529页 *
Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMX;Phan, J.等;Journal of Biological Chemistry;第285卷(第6期);第1570-1582页 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12115224B2 (en) 2017-10-27 2024-10-15 Ohio State Innovation Foundation Polypeptide conjugates for intracellular delivery of stapled peptides

Also Published As

Publication number Publication date
CA3080617A1 (en) 2019-05-02
JP2021501201A (ja) 2021-01-14
JP2023134675A (ja) 2023-09-27
US20230106131A1 (en) 2023-04-06
EP3700548A1 (en) 2020-09-02
CN111447941A (zh) 2020-07-24
CN117567639A (zh) 2024-02-20
JP7780253B2 (ja) 2025-12-04
EP3700548A4 (en) 2021-07-21
US12115224B2 (en) 2024-10-15
US11510991B2 (en) 2022-11-29
US20200276323A1 (en) 2020-09-03
WO2019084528A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
CN111447941B (zh) 用于细胞内递送装订肽的多肽缀合物
US12492224B2 (en) Bicyclic peptide ligands specific for PD-L1
JP7175887B2 (ja) ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法
US10023613B2 (en) Peptidomimetic macrocycles as modulators of MCL-1
US11673919B2 (en) Bicyclic peptidyl inhibitors
US12329799B2 (en) Peptidyl inhibitors of calcineurin-NFAT interaction
JP2022552839A (ja) 二環式ペプチドリガンド薬物コンジュゲート
US20220315631A1 (en) Stapled beta-catenin ligands
US20240368224A1 (en) Bicyclic peptidyl pan-ras inhibitors
CN107148425A (zh) 对mt1‑mmp特异性的双环肽配体
CN112585157A (zh) 用于结合整联蛋白αvβ3的肽配体
US20190185518A9 (en) Warhead-containing peptidomimetic macrocycles as modulators of bfl-1
WO2016208761A1 (ja) 薬物複合体
CN117836316A (zh) 能够抑制myc驱动的转录的共价蛋白质二聚体的合成

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant